Home >  News >  Industry >  Pharma News >  AstraZeneca chief says...

AstraZeneca chief says COVID-19 vaccine supply may meet, even outstrip demand in India by Q3

By - Ruchika Sharma
Published On 2021-01-31 04:30 GMT   |   Update On 2021-01-31 04:30 GMT
Advertisement

New Delhi: The supply of vaccines for Covid-19 may meet up or even outstrip the demand in India by the third quarter of this year, given the number of vaccines being developed in the country and its capacity, AstraZeneca Pharma India Country President and MD Gagan Singh said on Friday.

The pandemic has shown how resilient healthcare is, and how important pillar biopharmaceutical industry is as part of the healthcare ecosystem. Therefore, support for academic research, a vibrant healthcare system that embraces innovation is going to be very critical, he added.
"I am very hopeful given our enterprise, given the number of vaccines India is developing and the capacity available, hopefully in my own personal read, by quarter 3, we may actually have a situation where supply will meet up the demand or even outstrip," Singh said.
We must compliment our government also in its efforts towards getting the country in putting the plan for vaccination together and now in the rollout, he added.
Advertisement
For any vaccine to be meaningful in the current pandemic, it has to be made available broadly, equitably and timely. That is why AstraZeneca globally went around having supply agreements in place towards 3 billion doses covering 160 countries and more importantly at no profit during the pandemic, Singh said.
AstraZeneca's partnership in India with Serum Institute is a sub-licensing agreement of its molecule and they (Serum Institute) bring in close to 1 billion doses which are extremely important not only for India but also for low and middle income countries, he added.
Talking about the safety and efficacy of the company's vaccine, Singh said that in the month of December, Lancet enabled us to share a full disclosure of the Oxford programme interim analysis.
The results clearly showed that the vaccine is effective against Covid-19, and in particular with no severe infection and no hospitalisations in the vaccine group, he said, adding that this data was for over 11,000 plus volunteers across multiple countries.
He was speaking in a session on healthcare at a virtual event organised by TiE Delhi-NCR.
At the session, Apollo Hospitals Joint MD Sangita Reddy said that the vaccine is an incredible validation of the capability of India's manufacturing sector, it is a huge referendum on the global cooperation of sciences and manufacturers to bring something to humanity.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

State Drug Alert: Ciprofloxacin, Lorazepam, Albendazole Among 97 NSQ Samples Flagged in July

USFDA approves Teva Pharma generic Saxenda for weight loss

AbbVie to buy Gilgamesh Pharma Bretisilocin for Major Depressive Disorder

GSK Gepotidacin approved in UK for UTIs in females aged 12 years and older

AstraZeneca Imfinzi application granted priority review by USFDA for resectable early stage gastric, gastroesophageal junction cancers

46 Drug Batches Fail CDSCO Quality Test In July, Details

CDSCO Flags 8 Batches of Spurious Medicines, Including Popular Brands Augmentin, PAN 40

Assam: Rs 3 crore bottles of illegal cough syrup seized, 2 arrested